Objectives-To investigate the effects of chronic liver disease (CLD) on the structural and functional characteristics of right-sided heart chambers in patients with normal pulmonary artery pressure.
C ardiopulmonary complications are important sources of morbidity and mortality in patients with chronic liver disease (CLD). [1] [2] [3] Of these, cirrhotic cardiomyopathy is the most frequently observed cardiac complication, which was reported in nearly 50% of patients with CLD. 4, 5 Cirrhotic cardiomyopathy is characterized by an inadequate cardiac response to stress, left ventricular (LV) systolic and diastolic dysfunction, increased LV mass, and electrophysiologic abnormalities. 3 These latter changes are secondary to hemodynamic alterations, neuroendocrine activation, disruption of myocardial ion channels, and systemic inflammation induced by CLD. 6 The presence of cirrhotic cardiomyopathy marks a worse prognosis, as even mild diastolic dysfunction reduces survival in patients with CLD. 7 Similar to the alterations in the LV, several studies reported geometric and functional alterations in the right heart secondary to cirrhotic cardiomyopathy, including right ventricular (RV) dilatation and hypertrophy, right atrial (RA) enlargement, and diastolic dysfunction. [8] [9] [10] Notably, RV systolic performance, as measured with conventional parameters, did not seem to be affected by cirrhotic cardiac involvement, 11 although novel techniques such as RV myocardial strain imaging have not been used yet in this patient population. Assessing RV involvement in cirrhotic cardiomyopathy is somewhat more complex than the LV, since at least 20% of patients with CLD have increased pulmonary artery pressure, and an increase in the RV afterload per se can cause the aforementioned changes in the RV. 12 As previous studies did not systematically exclude patients with increased pulmonary artery pressure, it is not clear whether these changes are secondary to CLD or rather a consequence of an increased RV afterload. Thus, the extent of RV involvement in patients with CLD has not been fully elucidated yet. In this study, we aimed to analyze RV morphologic characteristics and function in patients with CLD and normal pulmonary artery pressure using 2-and 3-dimensional echocardiography and myocardial strain imaging and to investigate the correlation between the severity of CLD and the degree of RV involvement in the same patient population.
Materials and Methods

Study Population
For this study, patients with CLD who were followed as outpatients at the study institution were screened for inclusion and exclusion criteria. Patients who were older than 18 years and had a diagnosis of CLD at least 1 year before enrollment were eligible for participation. Exclusion criteria were as follows: previous diagnosis of dilated, restrictive, or hypertrophic cardiomyopathy; severe valvulopathy (more than mild aortic, mitral, or pulmonary regurgitation, organic tricuspid valve disease, more than mild aortic stenosis, or any degree of pulmonary of mitral stenosis); arrhythmogenic RV dysplasia; pulmonary embolism; pulmonary hypertension (PH) due to any etiology; severe coronary artery disease or previous myocardial infarction; heart failure with a preserved ejection fraction; rhythm other than sinus; frequent ventricular or atrial extrasystoles; a history of portopulmonary hypertension or hepatopulmonary syndrome; greater than stage 2 renal failure; a history of chronic lung disease; severe anemia (defined as hemoglobin < 7 g/dL) or recent (<3 months) major bleeding; and liver cancer. In addition, patients with echocardiographic evidence of reduced LV systolic function (defined as an ejection fraction of 50%), severe valvulopathy (as defined above), grade 2 or higher LV diastolic dysfunction, a peak tricuspid regurgitation velocity of 2.8 m/s or higher, or a pulmonary acceleration time of less than 105 milliseconds were excluded if any of those were detected during the echocardiographic evaluation. Finally, contrast agent injection with agitated saline was used to rule out hepatopulmonary syndrome in suspected patients. A total of 69 patients were initially screened, and 51 of 69 patients who fulfilled all of these criteria were included. Twenty-five participants without any previous known cardiopulmonary disorder or any systemic disorder that might cause RV dysfunction or PH served as controls. For all participants within the control group, LV systolic dysfunction or grade 2 or higher diastolic dysfunction, severe valvopathy, and suspected or definite PH (defined as a tricuspid regurgitation velocity of 2.8 m/s) were ruled out during the echocardiographic examination.
Anthropometric, demographic, and clinical information were recorded from all participants included to the study. Blood pressure was measured with an aneroid sphygmomanometer after 15 minutes of rest. The heart rate was measured synchronously with the blood pressure measurement. Patients with CLD were classified according to the Child-Pugh classification and original Model of End-Stage Liver Disease (MELD) score. For the purpose of CLD classification, blood was withdrawn from an antecubital vein with a 20-gauge needle, and sample blood was send to the laboratory within 1 hour. The serum albumin level, bilirubin level, prothrombin time, and international normalized ratio were measured from blood samples by standard biochemical analysis techniques.
The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Umraniye Research and Training Hospital. All participants gave their written informed consent before enrollment.
Echocardiographic Examinations
Echocardiographic examinations were performed with an ultrasound platform (Epiq; Philips Healthcare, Andover, MA) equipped with a 5-1-MHz transthoracic transducer (X5-1; Philips Healthcare). All parameters were measured 3 times, and an average of these measurements was used in the statistical analysis. Twodimensional and Doppler measurements (including tissue Doppler measurements) were performed and evaluated according to the American Society of Echocardiography guidelines. 13, 14 Right ventricular end-diastolic and end-systolic diameters were measured immediately above the tricuspid valve. Right ventricular end-diastolic and end-systolic areas were measured from the apical 4-chamber view, and the RV fractional area change was calculated as follows: RV end-diastolic area -RV endsystolic area/RV end-diastolic area. Tissue Doppler velocities were measured from lateral aspect of the tricuspid valve annulus. Early (E) and atrial (A) tricuspid inflow velocities were recorded by placing the pulsed wave Doppler cursor immediately above the tip of the tricuspid valve. The tricuspid regurgitation velocity was recorded by continuous wave Doppler imaging, and a complete flow envelope was obtained before making a measurement. The pulmonary acceleration time was measured by placing the pulsed wave Doppler cursor on the tip of pulmonary valve and defined as the time to reach the maximal pulmonary velocity. Myocardial performance index was calculated by using RV inflow and outflow recordings as defined before. The presence of RV hypertrophy was defined as an absolute RV thickness of 5 mm or greater as measured from the subcostal long-axis view immediately below the tricuspid valve. 14 For RA volume calculation, 4-beat full-volume 3-dimensional echocardiographic images were recorded from the apical 4-chamber view. Right atrial volume measurement was performed during end systole with commercially available computer software (QLAB; Philips Healthcare).
Measurement of RV Strain and Strain Rate
For longitudinal strain measurements, a speckle-tracking technique was preferred. Three cardiac cycles (loops) with a frame rate of 50 frames per second or higher were recorded from the apical 4-chamber view. Two sets of recordings were obtained from each participant and stored digitally. All stored recordings were analyzed with computer software (QLAB). The RV free wall was divided into 3 segments (basal, mid, and apical), and strain measurements were made for each segment. Mean RV free wall strain was defined as the average strain of all 3 segments. Although contraction of the interventricular septum was also quantified, it was not reported, as it is rather determined by the systolic function of the LV.
Statistical Analysis
Statistical analyses were performed with SPSS version 17.0 software (IBM Corporation, Armonk, NY). Continuous variables were reported as mean 6 standard deviation, whereas categorical variables were reported as percentages. The distribution of the continuous variables and equality of variances were analyzed by KolmogorovSmirnov and Levene tests, respectively. The Student t test was used for parameters with a normal distribution, whereas the Mann-Whitney U test was preferred for data with an inhomogeneous distribution. For categorical variables, v 2 or Fisher exact tests were preferred, with the latter used when the estimated cell value was less than 5. Depending on the severity of CLD, patients were further grouped into subgroup 1 (Child-Pugh A) and subgroup 2 (Child-Pugh B and C). Similar statistical techniques were used to analyze patients within subgroups. To analyze the correlation between the MELD score and various echocardiographic measures of RV geometry and function, the Spearman q was used. A univariate analysis and multivariate logistic regression analysis with forward stepwise selection criteria were used to find determinants of RV hypertrophy. All clinical parameters were included in the multivariate model regardless of the results of the univariate analysis. P < .05 was accepted as significant for all analyses.
To test interobserver variability, a second set of measurements were performed by a second investigator using the offline stored data. Three parameters (RV end-diastolic diameter, systolic velocity, and mean RV free wall strain) were measured by this second investigator from 10 random patients. The Cronbach a and intraclass correlation coefficient were calculated accordingly.
Results
Baseline demographic, clinical, and laboratory variables are given in Table 1 . In brief, age, sex, pulse rate, diastolic blood pressure, smoking, and existence of comorbidities were not significantly different between groups, whereas systolic blood pressure was significantly lower in the CLD group (P 5 .007). Although not significantly different, a higher ratio of participants in the control group were smokers. Table 2 summarizes echocardiographic findings in the groups. Although there was a tendency toward higher RV end-diastolic and end-systolic areas in the CLD group, these findings did not reach statistical significance (P 5 .09 and .07, respectively). Similar to the RV, the RA area, RA volume, and pulmonary artery diameter were similar between groups. Only RV free wall thickness was significantly higher in patients with CLD (P < .001; Figure 1 ). No other indices of RV geometry or systolic/diastolic function were different between the groups ( Table 2) .
Determinants of RV Free Wall Thickness
Compared to the control group, the frequency of RV hypertrophy was significantly higher in the patients with CLD (16.0% versus 0.0%; P 5 .038). A multivariate model that included all relevant clinical parameters was ACE indicates angiotensin-converting enzyme.
G€ unay et al-Right Heart Chambers in Chronic Liver Disease Without Pulmonary Hypertension constructed (Table 3) . Alcohol consumption was not included in the multivariate analysis, as the number of patients with active alcohol consumption was too low to be analyzed in a logistic regression model. Of the remaining parameters, the presence of CLD (P 5 .04; odds ratio, 11.35; 95% confidence interval, 1.067-120.878), weight, and body mass index were independent predictors of RV hypertrophy.
Echocardiographic Correlates of RV Free Wall Thickness in Patients With CLD An individual correlation analysis was performed for all relevant echocardiographic indices of RV and RA morphologic characteristics and systolic/diastolic function. Of all parameters plotted against RV free wall thickness in the CLD group, only the RV end-diastolic diameter (P 5 .018; r 5 0.334) and RA area (P 5 .017; r 5 0.335) had a significant correlation with RV free wall thickness ( Figure 2 ). However, the correlation coefficient was less than 0.5 for both parameters, thus showing a weak relationship between these parameters and RV free wall thickness.
Subgroup Analyses
In the subgroup analysis, patients within subgroup 1 tended to have lower mean RV free wall strain and a higher myocardial performance index, yet both findings did not reach statistical significance (Table 4 
strain and a trend toward lower RV mid free wall strain (221.25 6 7.27 versus 225.26 6 8.08; P 5 .08) compared to patients who were not receiving beta blocker treatment (n 5 21). Mean RV free wall strain (220.37 6 6.6 versus 224.07 6 6.52; P 5 .04) was also reduced in this subgroup of patients. Conventional parameters of RV morphologic characteristics and function did not differ between patients using beta blockers and those not using them. Patients receiving spironolactone treatment (n 5 11) had a significantly lower mean lateral systolic velocity value (12.43 6 1.25 versus 14.47 6 3.03 cm/s; P 5 .04) than those not receiving it, but other indices of RV systolic function and mean RV strain were similar between the groups. No similar associations were observed for patients using angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists or furosemide.
Reliability Analysis
Cronbach a values were 0.99, 0.99, and 0.98, and intraclass correlation coefficients were 0.98, 0.96, and 0.93 for the RV end-diastolic diameter, systolic velocity, and mean RV free wall strain, respectively.
Discussion
Key findings from this study can be summarized as follows: (1) in the presence of normal pulmonary artery pressure and pulmonary vascular resistance, right-sided heart chambers were not enlarged, and RV systolic and diastolic functions were not different from those of ageand sex-matched controls; (2) RV wall thickness was increased even in the absence of an increased afterload; (3) none of the parameters representing RV geometry or function, including increased RV thickness, had a binary or linear relationship with the severity of CLD, suggesting that RV hypertrophy is related to the presence of CLD per se rather than the severity of liver dysfunction; and (4) patients treated with a beta blocker had a small but significant reduction in mean RV strain, suggesting subclinical RV systolic dysfunction in this subgroup. However, a causal relationship between beta blocker use and reduced RV systolic performance is not clear and could not be established on the basis of these findings. Cirrhotic cardiomyopathy is the final result of several pathogenetic pathways that arise secondary to CLD. Most notable of these pathways are hyperdynamic circulation secondary to reduced systemic vascular resistance, activation of the renin-angiotensin-aldosterone system, and increased concentrations of endotoxins, cytokines, and bile acids in the systemic circulation due to portocaval shunts. 15 Since the mechanisms that lead to cirrhotic cardiomyopathy affect all regions of the heart, RV involvement is also expected in patients with CLD. However, up to 20% of patients with CLD have a concomitant increase in pulmonary systolic pressure, and 5% to 6% of patients waiting for liver transplantation have PH. 12, 16 Pulmonary hypertension induces pathologic changes in the RV even in the absence of cirrhotic cardiomyopathy. 17 Several studies found increased RV and RA dimensions, as well as increased RV free wall thickness, in patients with CLD. 9, 18, 19 In these studies, however, patients with high pulmonary artery pressure were not excluded systematically. In our study, we found that RV dimensions were similar to those of controls in patients with CLD and normal pulmonary artery pressure and pulmonary vascular resistance, thus suggesting that the changes in RV geometry are caused by PH rather than cirrhotic cardiomyopathy. In contrast, substantial RV hypertrophy was observed in our patient population, which indicates that RV hypertrophy is within the spectrum of alterations associated with cirrhotic cardiomyopathy, even in the absence of an increased RV afterload (Table 2) . A possible explanation of RV hypertrophy could be activation of the reninangiotensin-aldosterone system secondary to CLD, which induces myocyte hypertrophy, fibrosis, and apoptosis. 16 As already mentioned, this pathogenetic mechanism has been implied as one of the main pathways that lead to LV hypertrophy in cirrhotic cardiomyopathy. Several animal studies have found that activation of the renin-angiotensin-aldosterone system could lead to RV hypertrophy, and blockage of the renin-angiotensinaldosterone system could reduce RV thickness in animal models. 20, 21 Still, it should be noted that available data are inadequate to suggest that renin-angiotensinaldosterone system activation per se could lead to RV hypertrophy in the absence of PH in humans, even though this mechanism remains a possible explanation.
Studies using myocardial deformation imaging have shown that subclinical ventricular contractile dysfunction is present in several cardiovascular conditions, which were originally considered diseases with normal or nearnormal systolic function. 22 Cirrhotic cardiomyopathy was previously known as a cardiac disorder that predominantly affects diastolic function with relative sparing of systolic function. A recent study by Kazankov et al 23 showed reduced global LV strain in patients with cirrhotic cardiomyopathy, thus suggesting the presence of subclinical LV contractile dysfunction in patients with CLD and a normal LV ejection fraction. Although the RV ejection fraction was never assessed for patients with cirrhotic cardiomyopathy, previous studies indicated that RV longitudinal contraction was preserved, even in patients with increased pulmonary artery pressure. 9, 16 Our findings were concordant with the previous literature and showed normal RV longitudinal contractility in patients with CLD, even when measured by a sensitive and quantitative method. Therefore, these results suggest that RV systolic dysfunction is not a component of cirrhotic cardiomyopathy. Since patients with an increased RV afterload were excluded from this study, these results should not be generalized to patients with hepatopulmonary syndrome or portopulmonary hypertension.
In contrast, RV diastolic dysfunction was universally found in all studies that enrolled patients with CLD. 9, 11, 18 In children with CLD secondary to hepatitis B, the isovolumic relaxation time was significantly increased, whereas the velocity of the early diastolic wave on tissue Doppler imaging was significantly decreased. 11 Karabulut et al 9 found increased RV free wall thickness, a reduced tricuspid E/A ratio and myocardial early diastolic wave velocity, and higher RV thickness in patients with CLD. Our findings regarding RV diastolic function contrasted with the previous findings, as neither the E/A ratio nor early or atrial myocardial tissue Doppler velocities were different in patients with CLD. This latter finding was rather surprising, given that patients with CLD had increased RV free wall thickness compared to controls, and ventricular hypertrophy is a wellestablished causative factor in diastolic dysfunction. 24 As mentioned before, previous studies included patients with a high afterload, which could explain the lack of RV diastolic dysfunction in this study, since the diastolic properties of the myocardium are load dependent. 25 One older study that stratified patients with CLD according to pulmonary artery pressure showed that patients with high pulmonary artery pressure more frequently had diastolic dysfunction (assessed only by the E/A ratio), whereas patients with pulmonary artery pressure lower than 30 mm Hg had normal diastolic properties of the RV, thus illustrating that the hemodynamic load could be a more important determinant of RV geometry and function compared to direct involvement of the RV secondary to cirrhotic cardiomyopathy. 19 An increased afterload also leads to more pronounced RV hypertrophy, which may also explain why RV free wall thickness in this study was less pronounced (4.15 6 0.64 mm; average systolic pulmonary artery pressure, 26.08 6 7.6) compared to the findings of Karabulut et al, 9 who had found a more marked increase in RV free wall thickness (5.1 6 1.0 mm; average mean pulmonary artery pressure, 40.6 6 5.3 mm Hg). Therefore, it could be suggested that RV hypertrophy is associated with cirrhotic cardiomyopathy even in the absence of PH, yet an increased afterload and a further increase in RV free wall thickness are required for RV diastolic dysfunction.
The correlation between the degree of underlying liver disease and the severity of cirrhotic cardiomyopathy varied between studies. For the LV, one study showed that patients with Child-Pugh A CLD had increased LV wall thickness and worse diastolic function compared to patients with Child-Pugh C CLD, thus suggesting that the severity of CLD does not correlate with cardiac impairment. 26 Another study, however, suggested that the left atrial and LV end-diastolic diameters correlate with the MELD score; albeit reported correlation coefficients for both analyses were rather low (r 5 0.32 for left atrial diameter; r 5 0.18 for LV end-diastolic diameter). 27 For the RV, the latter study suggested that the RV end-diastolic diameter did not have a linear correlation with the MELD score, and no difference was found between patients with a MELD score of 16 or greater compared to patients with a MELD score of less than 16. 27 One study found a weak-to-moderate correlation between liver fibrosis and the degree of diastolic impairment in the RV, but it did not report pulmonary artery pressure or the relationship between pulmonary artery pressure and diastolic dysfunction in its cohort. 11 Findings from our present study suggest that patients with more-advanced CLD, defined as Child-Pugh B or C, did not have abnormal diastolic properties compared to those classified as Child-Pugh A and healthy controls. Moreover, there was a trend toward increased RV free wall thickness and a higher myocardial performance index (corresponding to worse systolic and diastolic performance of the RV) in patients with Child-Pugh A CLD, which were remarkably similar to the findings noted for the LV by Pozzi et al. 26 Although all of the studies were inherently limited by small sample sizes and their cross-sectional nature, on aggregate, we think that the available evidence does not support a relationship between the degree of liver dysfunction and the severity of cirrhotic cardiomyopathy.
Several drugs with potent cardiovascular effects, such as beta blockers, inhibitors of the renin-angiotensinaldosterone system, and diuretics, are widely used to treat portal hypertension and ascites associated with CLD. 28 Unfortunately, the available information on cardiac effects of these drugs in patients with CLD is severely limited, and decision making in clinical practice is based on studies that did not include patients with CLD. In some instances, harmful effects of these drugs, particularly beta blockers, may outweigh beneficial effects in patients with severe CLD. 28, 29 Withdrawal of beta blockers in patients with portopulmonary hypertension is associated with improved exercise capacity and cardiac output. 30 Our subgroup analysis showed that patients using beta blockers had reduced RV systolic contractility compared to patients not using them. This latter finding could be secondary to negative inotropic effects of beta blockers and can offer a mechanistic explanation for the harm associated with beta blockers in patients with severe CLD, since reduction of RV contractility is associated with adverse cardiovascular outcomes in other cardiovascular disorders such as congestive heart failure. 31 However, it must be reminded that patients treated with beta blockers could have additional unaccounted-for factors (such as the presence of portal hypertension or more severe CLD) that can affect RV contractility, and the clinical importance of reduced RV strain in patients with CLD is unclear. Neither the design nor the power of this study was adequate to make a detailed analysis of coexisting conditions or outcomes, so these findings must be regarded as hypothesis generating rather than definite.
This study had some limitations. It enrolled a limited number of patients from a single center. The small sample size reduced the power of the study and increased the probability of a type II error. A selection bias or other types of biases could be present in all observational nonrandomized studies. Echocardiography-based measurements are subject to considerable interobserver and intraobserver variability. Although intraclass correlation coefficients indicate that the intraobserver variability was acceptable for the parameters investigated in this study, measurement errors could not be completely ruled out. Therefore, an external validation of the present findings would be highly desirable. Although the reference standard technique for diagnosing (and also excluding) PH is right heart catheterization, echocardiographic measurement of the tricuspid regurgitation velocity was used to exclude patients with PH. Although the echocardiographic estimation of pulmonary artery pressure is inadequate for diagnosing PH per se, PH is highly unlikely in the presence of a tricuspid regurgitation velocity of 2.8 m/s or less. 32 As catheter-based measurement of pulmonary artery pressure is invasive, and it would not be ethical to perform a right heart catheterization in patients without a clinical suspicion of PH, we consider that the use of echocardiography-based measurements in lieu of right heart catheterization was justified. Only RV free wall longitudinal strain was measured by deformation imaging. Although most RV contraction happens in the longitudinal direction, it is theoretically possible to obtain different results by measuring RV strain in other (ie, circumferential) directions.
In conclusion, in patients with CLD but without PH, RV free wall thickness was found to be significantly higher than that in controls, whereas all other measures of RV geometry and systolic/diastolic function were normal. Therefore, in the absence of increased pulmonary artery pressure, the sole manifestation of cirrhotic cardiomyopathy in the RV is RV hypertrophy, which probably reflects activation of the renin-angiotensin-aldosterone system secondary to CLD. This hypertrophy of the RV does not appear to cause a disruption of RV systolic or diastolic function. All other alterations in the RV reported by previous studies might be secondary to an increase in the RV afterload rather than a consequence of cirrhotic cardiomyopathy. Patients with CLD who were treated with beta blockers had a small but statistically significant reduction in regional and mean RV free wall strain, but our study design was inadequate to suggest a causative relationship between beta blocker treatment and RV systolic dysfunction. Future studies elaborating the exact cause and clinical relevance of RV hypertrophy and the cardiovascular effects of beta blockers in patients with CLD are warranted.
